Payment overview · 2025
General Payments
$276.84
8 reported records · 4 companies
Healthcare provider profile · identity verified
Robert A Clarke, MD
Allopathic & Osteopathic Physicians|Internal Medicine · EAST ORANGE, NJ · NPI 1114934007
Verified facts
What the public records show
CMS Open Payments records show Robert A Clarke, MD received $276.84 in general payments during 2025 across 8 reported records.
Xeris Pharmaceuticals, Inc. accounted for 55.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 4 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Kerendia.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Linzess by this doctor in 2024.
Bayer Healthcare Pharmaceuticals Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Kerendia as an associated drug or biological on 138674 records involving 48458 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Kerendia by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $154.56 | 55.8% | 5 | 2025 |
| Cook Medical LLC | Unresolved — no canonical attribution shown | $89.48 | 32.3% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $17.60 | 6.4% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $15.20 | 5.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $276.84 | 8 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| GVOKE HYPOPEN Normalized: gvoke hypopen |
Drug | Xeris Pharmaceuticals, Inc. | $154.56 | 5 | 2025 |
Source payment records
|
|||||
| ZENITH SPIRAL-Z Normalized: zenith spiral z |
Device | Cook Medical LLC | $89.48 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $17.60 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $15.20 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Kerendia kerendia |
2025 | Kerendia | 2024 | 21 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| Bayer Healthcare Pharmaceuticals Inc. Exact reporting entity; no affiliate inference |
2025 | Kerendia open payments reported associated product |
CMS Open Payments — General Payments 138674 supporting records · 48458 recipient NPIs · example record 1225434663 |
Kerendia · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 664 | 118 |
| Amlodipine Besylate | Amlodipine Besylate | 572 | 95 |
| Eliquis | Apixaban | 367 | 48 |
| Gabapentin | Gabapentin | 350 | 65 |
| Pantoprazole Sodium | Pantoprazole Sodium | 337 | 64 |
| Risperidone | Risperidone | 297 | 27 |
| Trazodone Hcl | Trazodone Hcl | 297 | 31 |
| Metformin Hcl | Metformin Hcl | 275 | 50 |
| Divalproex Sodium | Divalproex Sodium | 252 | 29 |
| Levothyroxine Sodium | Levothyroxine Sodium | 221 | 18 |
| Losartan Potassium | Losartan Potassium | 219 | 35 |
| Donepezil Hcl | Donepezil Hcl | 205 | 21 |
| Furosemide | Furosemide | 190 | 41 |
| Tamsulosin Hcl | Tamsulosin Hcl | 188 | 27 |
| Mirtazapine | Mirtazapine | 185 | 39 |
| Levetiracetam | Levetiracetam | 178 | 22 |
| Clopidogrel | Clopidogrel Bisulfate | 166 | 36 |
| Metoprolol Tartrate | Metoprolol Tartrate | 162 | 29 |
| Lisinopril | Lisinopril | 150 | 28 |
| Metoprolol Succinate | Metoprolol Succinate | 135 | 18 |
| Carvedilol | Carvedilol | 133 | 22 |
| Benztropine Mesylate | Benztropine Mesylate | 124 | 16 |
| Potassium Chloride | Potassium Chloride | 112 | 19 |
| Quetiapine Fumarate | Quetiapine Fumarate | 106 | 15 |
| Lactulose | Lactulose | 105 | 15 |
| Hydrochlorothiazide | Hydrochlorothiazide | 103 | 17 |
| Baclofen | Baclofen | 100 | 13 |
| Escitalopram Oxalate | Escitalopram Oxalate | 100 | 13 |
| Latanoprost | Latanoprost | 95 | 17 |
| Hydralazine Hcl | Hydralazine Hcl | 94 | 23 |
| Memantine Hcl | Memantine Hcl | 93 | 14 |
| Montelukast Sodium | Montelukast Sodium | 90 | 18 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 89 | 11 |
| Duloxetine Hcl | Duloxetine Hcl | 89 | 11 |
| Simvastatin | Simvastatin | 88 | 13 |
| Ibuprofen | Ibuprofen | 84 | 19 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 80 | 25 |
| Entresto | Sacubitril/Valsartan | 77 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 77 | 23 |
| Xarelto | Rivaroxaban | 75 | suppressed |
| Jardiance | Empagliflozin | 74 | 13 |
| Brimonidine Tartrate | Brimonidine Tartrate | 68 | suppressed |
| Januvia | Sitagliptin Phosphate | 66 | suppressed |
| Nifedipine Er | Nifedipine | 63 | 13 |
| Aripiprazole | Aripiprazole | 61 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 61 | suppressed |
| Omeprazole | Omeprazole | 61 | 15 |
| Tradjenta | Linagliptin | 61 | suppressed |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 59 | 13 |
| Buspirone Hcl | Buspirone Hcl | 53 | suppressed |
| Finasteride | Finasteride | 52 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 49 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 48 | 11 |
| Meloxicam | Meloxicam | 48 | suppressed |
| Hydromorphone Hcl | Hydromorphone Hcl | 47 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 44 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 42 | suppressed |
| Clonazepam | Clonazepam | 41 | suppressed |
| Spironolactone | Spironolactone | 40 | 11 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 39 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 37 | 12 |
| Glimepiride | Glimepiride | 37 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 37 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 35 | suppressed |
| Sevelamer Carbonate | Sevelamer Carbonate | 35 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 35 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 35 | suppressed |
| Valproic Acid | Valproic Acid (As Sodium Salt) | 35 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 34 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 34 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 34 | suppressed |
| Olanzapine | Olanzapine | 34 | suppressed |
| Colchicine | Colchicine | 33 | suppressed |
| Novolog Flexpen | Insulin Aspart | 33 | suppressed |
| Timolol Maleate | Timolol Maleate | 33 | suppressed |
| Sucralfate | Sucralfate | 31 | suppressed |
| Allopurinol | Allopurinol | 30 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 30 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 30 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 29 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 28 | suppressed |
| Santyl | Collagenase Clostridium Hist. | 28 | 11 |
| Budesonide | Budesonide | 27 | suppressed |
| Dorzolamide-Timolol | Dorzolamide Hcl/Timolol Maleat | 26 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 26 | suppressed |
| Silver Sulfadiazine | Silver Sulfadiazine | 26 | 11 |
| Torsemide | Torsemide | 26 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 26 | suppressed |
| Dutasteride | Dutasteride | 25 | suppressed |
| Novolog | Insulin Aspart | 25 | suppressed |
| Phenytek | Phenytoin Sodium Extended | 25 | suppressed |
| Pregabalin | Pregabalin | 25 | suppressed |
| Dorzolamide Hcl | Dorzolamide Hcl | 24 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 24 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 23 | suppressed |
| Humira(Cf) Pen | Adalimumab | 23 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 23 | suppressed |
| Mupirocin | Mupirocin Calcium | 23 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 22 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 22 | suppressed |
| Prednisone | Prednisone | 22 | 14 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 21 | suppressed |
| Kerendia | Finerenone | 21 | suppressed |
| Nystatin | Nystatin | 21 | suppressed |
| Brilinta | Ticagrelor | 20 | suppressed |
| Calcium Acetate | Calcium Acetate | 20 | suppressed |
| Chlorpromazine Hcl | Chlorpromazine Hcl | 20 | suppressed |
| Enoxaparin Sodium | Enoxaparin Sodium | 20 | suppressed |
| Heparin Sodium | Heparin Sodium,porcine | 20 | 12 |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 20 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 20 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 20 | suppressed |
| Ziprasidone Hcl | Ziprasidone Hcl | 20 | suppressed |
| Albuterol Sulfate | Albuterol Sulfate | 19 | suppressed |
| Atenolol | Atenolol | 19 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 19 | suppressed |
| Glipizide | Glipizide | 19 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 19 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 19 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 19 | suppressed |
| Amantadine | Amantadine Hcl | 18 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 18 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 18 | suppressed |
| Insulin Lispro | Insulin Lispro | 18 | 11 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 18 | suppressed |
| Buprenorphine-Naloxone | Buprenorphine Hcl/Naloxone Hcl | 17 | suppressed |
| Chlorthalidone | Chlorthalidone | 17 | suppressed |
| Fiasp | Insulin Aspart (Niacinamide) | 17 | suppressed |
| Levemir | Insulin Detemir | 17 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 17 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 17 | suppressed |
| Fiasp Flextouch | Insulin Aspart (Niacinamide) | 16 | suppressed |
| Humalog | Insulin Lispro | 16 | suppressed |
| Minoxidil | Minoxidil | 16 | suppressed |
| Sodium Chloride | 0.9 % Sodium Chloride | 16 | 12 |
| Alcohol Pads | Alcohol Antiseptic Pads | 15 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 15 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 15 | 11 |
| Famotidine | Famotidine | 15 | suppressed |
| Lansoprazole | Lansoprazole | 15 | suppressed |
| Nystop | Nystatin | 15 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 15 | suppressed |
| Trihexyphenidyl Hcl | Trihexyphenidyl Hcl | 15 | suppressed |
| Ammonium Lactate | Ammonium Lactate | 14 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 14 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 14 | suppressed |
| Linzess | Linaclotide | 14 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 14 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 14 | suppressed |
| Biktarvy | Bictegrav/Emtricit/Tenofov Ala | 13 | suppressed |
| Levofloxacin | Levofloxacin | 13 | suppressed |
| Mupirocin | Mupirocin | 13 | suppressed |
| Naltrexone Hcl | Naltrexone Hcl | 13 | suppressed |
| Atovaquone | Atovaquone | 12 | suppressed |
| Ceftriaxone | Ceftriaxone Sodium | 12 | suppressed |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 12 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 12 | suppressed |
| Flucytosine | Flucytosine | 12 | suppressed |
| Lorazepam | Lorazepam | 12 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 12 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 12 | suppressed |
| Misoprostol | Misoprostol | 12 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 12 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 12 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 12 | suppressed |
| Abilify Maintena | Aripiprazole | 11 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 11 | suppressed |
| Haloperidol | Haloperidol | 11 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 11 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 11 | suppressed |
| Lamivudine | Lamivudine | 11 | suppressed |
| Morphine Sulfate | Morphine Sulfate | 11 | suppressed |
| Nitroglycerin Patch | Nitroglycerin | 11 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 11 | suppressed |
| Ozempic | Semaglutide | 11 | suppressed |
| Sotalol | Sotalol Hcl | 11 | suppressed |
| Tivicay | Dolutegravir Sodium | 11 | suppressed |
| Valsartan | Valsartan | 11 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $276.84 · 8 records | Xeris Pharmaceuticals, Inc. | GVOKE HYPOPEN, Kerendia, VRAYLAR, ZENITH SPIRAL-Z | 2 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Kerendia play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error